



Partners

Advisor

 Grants

Grants

KEBIC PROJECT

REGIONE TOSCANA / FINANZIAMENTI REGIONALI PER RICERCA E SVILUPPO POR CREO FESR 2007-2013 BANDO UNICO R&S - LINEA A

- TITLE: Design of a knowledge database for biosimulation and increase in predictivity and translational productivity of preclinical data in the brain ischemia field.

The main goal of the project KEBIC is to create a knowledge database which collects and elaborates the results of a number of biological analysis performed on a brain ischemia animal model, integrating data and extrapolating the significance in their correlations. This integrated data system should allow the determination of the existence of such analytical parameters which could indicate the predictivity and the translation of the preclinical model into the human pathology.

TALCO PROJECT

REGIONE TOSCANA / FINANZIAMENTI REGIONALI PER RICERCA E SVILUPPO POR CREO FESR 2007-2013 BANDO NEGOZIALE ATTIVITA' 1.1 - LINEA DI INTERVENTO 1.1.C.

- TITLE: Cytotoxic cell line based Orphan Drug (TALL-104) against ovarian cancer

The goal of the project TALCO is to characterize the TALL-104 cell line from a molecular biological point of view to clarify the mechanisms of their cytotoxic activity and their ability to recognize cancer from normal cells, including their capability to reach the tumor site; in order to determine TALL-104 cell line efficacy in a specific pathology like ovarian cancer, through both in vitro or in vivo on animal model studies. Moreover, to confirm the efficacy and safety in a clinical trial with 40 patients affected by such pathology. The achievement of these goals should result in the availability of a new advanced and innovative therapy, extremely valuable in comparison to current existing therapies in this field, including the autologous cell therapies. In fact, TALL-104 could be the first heterologous cell therapy to be developed across the world.

the first heterologous cell therapy to be developed across the world.

ACTILA PROJECT

REGIONE TOSCANA / FINANZIAMENTI REGIONALI PER RICERCA E SVILUPPO POR CREO
FESR 2007-2013 BANDO UNICO R&S ANNO 2012 - Linea B

- TITLE: New multifunctional technology platform for immunotherapy in cancer: synergy among adoptive allogeneic cell therapy, monoclonal antibodies and immunostimulating molecules

The goal of the project is to tackle on tumoral pathologies potentiating an already native effective technology platform based on cytotoxic T-lymphocytes (TALL-104). Several strategies can be adopted to modify the T-cells to empower further modes of action; the T-lymphocytes can be modified either expressing antibodies capable to selectively link to the tumour or in order to produce a more cytotoxic mutant IL-2. Applying such multifunctional strategies will definitely reduce the escape of tumoral cells.

[Home Page](#) [About Galileo Research](#) [News](#) [Contacts](#) [Privacy Policy](#) [Cookie Policy](#) [Site Map](#) [Credits](#)

GALILEO RESEARCH s.r.l. Sede Legale: Via del Paradiso, 6 - 56019 - Vecchiano Loc. Migliarino Pisano - Phone +39.050.31.54.283 - Fax +39.050.80.33.38
Fiscal Code and Pisa Trade Number 1855640502 - REA Pisa N° 160639/2011 - Partita IVA 01855640502 Capital Stock € 100.000 fully paid in
Company subject to management and coordination by MDM HOLDING S.p.A. Pisa (Fiscal ID 01410690505)